Financial Highlights and Market Update

India (Domestic Market) 9 ■ Domestic market sales received strong demand during the quarter accounting to 77% y-o-y growth ■ The new capacities being made available for the domestic market has helped ramp up volume growth in the core portfolio of products Q1 FY22: Rs. 2,270 Mn YoY Growth: 77% India (Domestic Market) To support the domestic market during the second wave of COVID-19, we ramped up supply of essential drugs like Remdesivir and Enoxaparin considering the requirement for Indian patients ■ New launches: Q1 FY22: 1 Product SKU Q1 FY21 Revenue Contribution 15% Q1 FY22 20% GLAND

View entire presentation